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Abstract 
The method reported for isolation of ubiquinol-cytochrome-c reductase complex from submitochondrial particles was modified to 
yield a preparation for crystallization. The cytochrome bq complex was first crystallized in large thin plate form and diffracts X-rays to 7 
A resolution in the presence of mother liquor. This crystalline complex was enzymatically active and contains ten protein subunits. It had 
33 tool phospholipid and 0.6 mol ubiquinone per tool protein. With slightly modified crystallization conditions, different crystal forms 
were obtained. Crystals grown in the presence of 20% glycerol diffracted X-rays up to 2.9 ,~ resolution using a synchrotron source. Four 
heavy atom derivatives have been obtained. The 3-D structure of the cytochrome bc~ complex was solved to 3.4 A resolution. Crystalline 
cytochrome bc~ complex is a dimer: most of the masses of core proteins I and II protrudes from the matrix side of the membrane, 
whereas the cytocbrome b protein is located mainly within the membrane. There are 13 transmembrane h lices in each monomer. Most of 
the mass of cytochrome c~ and iron-sulfur protein including their redox centers are located on the cytoplasmic side of the membrane. The 
distances between these redox centers have been determined, and several electron transfer inhibitor binding sites in the complex have 
been located. 
Keywords: Mitochondrial cytochrome bc I complex; Electron transport: Protein crystallization; Co-crystallization of cytochrome bCl-Cytochrome c 
complex: Inhibitor complex 
1. Introduction 
Cytochrome bc I complex (commonly known as Com- 
plex III or ubiquinol-cytochrome-c reductase) is a segment 
of the mitochondrial respiratory chain which catalyzes 
antimycin-sensitive electron transfer from ubiquinol to cy- 
tochrome c [1,2]. The reaction is coupled to the transloca- 
tion of protons across the mitochondrial inner membrane 
to generate a proton gradient and membrane potential for 
ATP synthesis. Bovine heart mitochondrial cytochrome 
bc~ complex was first isolated in 1962 [1]; since then 
several purification methods have been introduced [3-6]. 
The purified cytochrome bc~ complex contains 11 protein 
subunits, as revealed by high resolution sodium dodecyl- 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
[7,8]. The amino acid sequences of all subunits are known, 
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some of them determined by peptide sequencing [9-14] 
and others deduced from nucleotide sequences [15-17]. 
The essential redox components of the cytochrome bc~ 
complex are: two b cytochromes (b565 and b562) , one  
c-type cytochrome (cl), one high potential iron-sulfur 
cluster (2Fe-2S Rieske center), and a ubiquinone. 
As a result of recent intensive investigation into the 
electron transfer and proton translocation mechanisms, in- 
vestigators in the field are now generally in favor of the 
proton motive Q-cycle hypothesis [18,19]. The key feature 
of the Q-cycle hypothesis is the involvement of two sepa- 
rate quinone/quinol binding sites: one at which quinol is 
oxidized (Qo) and another at which quinone is reduced 
(Qi). According to the Q-cycle, quinol is first oxidized by 
Rieske iron sulfur center to generate a reactive semiquinone 
which reduces the low-potential cytochrome b heme (b E). 
The reduced b L rapidly transfers an electron to the high- 
potential cytochrome b heme (b H) located on the opposite 
side of the membrane. The reduced b H is then oxidized by 
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a quinone or semiquinone at the Qi site. Proton transloca- 
tion thus occurs as the result of deprotonation f QH 2 at 
the Qo site and protonation of the reduced Q at the Qi site. 
The Q-cycle mechanism is supported by several experi- 
mental observations such as the oxidant-induced reduction 
of cytochrome b [20,21], the detection of antimycin-sensi- 
tive and -insensitive transient Q radicals [22,23], and the 
2H ÷ ejection per one electron transfer in cytochrome bc l 
complexes from many sources [25-27]. Photoaffinity stud- 
ies [28,29] using photoactivatable azido-ubiquinone d riva- 
tives have located the two possible quinone binding do- 
mains in cytochrome b protein. The involvement of cy- 
tochrome b562 at  the Qi  site is suggested by the different 
EPR characteristics of cytochrome b562 in the presence 
and absence of Q [30]. 
Chemical labeling and proteolytic enzyme digestion 
studies have provided substantial information concerning 
the spatial arrangement of this enzyme complex in the 
membrane [8]. Amino acid sequence analysis of cy- 
tochrome b [31,32] and the biophysical measurements 
[33-35] have predicted separate locations for the two b 
hemes. Mutagenesis studies [36] have contributed substan- 
tially to the structural study of the cytochrome bc I com- 
plex. However, the lack of knowledge of three-dimen- 
sional structure has long been an obstacle. The recent 
success in protein crystallization of the cytochrome bc~ 
complex [37-44] provides an opportunity for structural 
analysis of this large membrane protein complex. 
Over the past two decades, we have used multiple 
approaches to investigate the cytochrome bcl complex: 
protein components resolution and reconstitution, organic 
syntheses of ubiquinone derivatives and quinone-like in- 
hibitors, molecular genetics manipulation and protein X-ray 
crystallography. In this review we summarize our work on 
the X-ray crystallographic studies of this complex, empha- 
sizing protein crystallization and structure analysis. For 
other work on this and related complexes, excellent re- 
views are available [45,46]. 
2. Preparation of cytochrome bc~ complex 
Bovine heart mitochondrial cytochrome bcj complex 
(or Complex III) was first isolated from NADH-cyto- 
chrome-c reductase in 1962 [1]. This method is still used 
by many investigators [38,40]. Trumpower and co-workers 
developed a method for isolation of bc~ complexes from 
various sources, which involves expensive laurylmaltoside 
and two ion exchange column chromatography [6]. The 
cytochrome bc l complex used in our laboratory is pre- 
pared from a highly purified succinate-cytochrome-c r  
ductase preparation [4]. Succinate dehydrogenase in exten- 
sively dialyzed succinate-cytochrome-c r ductase is solubi- 
lized and removed upon alkalization (to pH 10) under 
anaerobic onditions. The resulting residue is termed the 
cytochrome bc~ particle and contains both cytochrome bc~ 
complex and a protein fraction (QPs) that converts ucci- 
nate dehydrogenase into succinate-Q reductase. The cy- 
tochrome bc~ particle is capable of reconstitution with 
pure succinate dehydrogenase to form succinate-cyto- 
chrome-c reductase. Highly purified cytochrome bc~ com- 
plex is obtained upon solubilization of the bc~ particle by 
deoxycholate and removal of QPs and other contaminants 
by a four-step ammonium acetate fractionation [4]. The 
purified complex contains 8.3 nmol cytochrome b, 4.7 
nmol cytochrome c 1, 3.5 nmol ubiquinone and 250 nmol 
phospholipid per mg protein. For protein crystallization the 
number of steps of ammonium acetate fractionation was 
increased to 15. The specific activity of the purified com- 
plex is 11 ~mol cytochrome c reduced per min per nmol 
cytochrome b at 23°C. When the purified complex is 
subjected to high resolution SDS-PAGE [7,8] eleven pro- 
tein bands are observed. 
Table 1 
Cytochrome b-cj complex crystals obtained by different investigators 
Investigators Space group Resolution Unit cell dimension Solvent content V m Detergent used 
(,~) (,~) (%) (.~3) in iso lat . / in  crystal. 
Yue et al. (1991) P4122 low a = b = 159, c = 593 69.4 4.3 SC, DOC/DMG 
Kubota et al. (1991) P2 j  7.5 a = 196, b = 179 - 4.4 DOC/SML 
c = 253, 13 = 97 ° 
Berry et al. (1992) P6122 4.7 a = b = 212, c = 352 65.7 4.96 LM/OG 
orP6522 
Yu et al. (1994) I4~22 4.5 a = b = 157, c = 590 70 4.0 SC, DOC/DMG 
Kawamoto et al. (1994) P61(P65) 6.5 a = b = 131, c = 720 - 3.9 DOC/SML 
or P41(P43) a = b = 190, c = 445 4.4 
Berry et al. (1995) C2221 3.8 a = 384, b = 118c = 177 - 4.35 LM/OG 
Lee et al. (1995) 14122 3.3 a = b = 153, c = 597 - - LM/HECAMEG 
Xia et al. (1996) 14122 2.9 a = b = 153.5, 69.4 4.0 SC, DOC/  
c = 597.7 SPC or DMG 
DMG, decanoyl-N-methylglucamide; DOC,  deoxyy cholate; HECAMEG,  6-O-(N-heptyl-carbamoyl)-methyl-ct-D-glucopyranoside; LM, lauraryl maltoside; 
OG, octyl a-D-glucopyranoside; PC, phosphotidylcholine; SC, sodium cholate; SML, sucrose monolaurate; SPC, short side chained-PC; V m, Matthews'  
coefficient. 
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Fig. 1. Crystals of cytochrome bcj complex grown under different conditions. (A), Native cytochrome bc~ complex; (B), Cytochrome c:cytochrome bcj 
complex; (C), UHDBT inhibited cytochrome bc] complex; (D), Stigmatellin i hibited cytochrome bc I complex; (E), Stigmatellin/antimycin inhibited 
cytochrome b£ 1 complex; and (F) Antimycin/myxothaizole inhibited cytochrome bc I complex. 
Fig. 2. Molecular shape of crystalline cytochrome bc 1 complex, inter-twined dimer. 
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3. Crystallization of cytochrome bc I complex 
Purified cytochrome bcl complex in 50 mM Tris-Cl 
buffer (pH 7.8), containing 0.67 M sucrose, was first 
crystallized in 6% polyethylene glycol-4000 (PEG) in the 
presence of 0.25 M sodium chloride, 1.8% heptanetriol, 
0.04% decanoyl-N-methyl-glucamide. Good-sized crystals 
formed within 2-4 weeks. The largest crystals grown in a 
Pasteur pipette had dimensions of 4 X 2 X 1 ram. Although 
the crystals showed a high degree of birefringence under 
polarized light, they diffracted X-rays only at low resolu- 
tion [37]. 
When crystals are grown in X-ray capillary tubes in 50 
mM MES buffer (pH 7.0), instead of 50 mM Tris-Cl 
buffer (pH 7.8), they diffract X-rays to 7 ,~ resolution in 
the presence of mother liquor using a Xuong/Hamlin area 
detector. The crystals have the symmetry of the tetragonal 
space group 14122 with cell constants a = b = 153.5 A, 
c =597.7A. Assuming one cytochrome bc 1 complex 
molecule per asymmetric unit, the crystals would have a 
solvent content of 70%. Removal of the mother liquor 
from the crystals causes severe loss of diffraction quality. 
Moreover, the tendency of the crystals to move in a 
liquid-filled capillary tube makes data collection difficult. 
To circumvent these difficulties, we developed a method to 
crystallize cytochrome bq complex in the gel state [44]. 
Purified ubiquinol-cytochrome-c reductase, 20 mg/ml, in 
50 mM MES buffer (pH 7.0), containing 0.67 M sucrose 
was mixed, at 18°C, with an equal volume of precipitating 
solution containing 0.08% decanoyl-N-methyl-glucamide, 
3.6% heptanetriol, 0.5 M sodium chloride, 12% poly- 
ethylene glycol, and 0.8-0.4% low gelling temperature 
agarose. The mixture was placed in capillary tubes, cooled 
to 4°C, overlaid with equilibrating solution, and incubated 
in a shock-free nvironment at 4°C. Under these condi- 
tions, cytochrome-bq complex crystals formed within 2-4 
weeks. The size, shape and diffraction quality of these 
crystals approached those obtained from the liquid state. 
When crystallization was carried out under the reduced 
pressure, the rate of crystal growth increased substantially 
at the expense of crystal size. 
Recently, conditions used for growing cytochrome bc 1 
complex crystals were further modified to improve crystal 
diffraction quality. The cytochrome bcj complex was di- 
luted with an equal volume of 0.5 M sucrose and precipi- 
tated with an equal volume of 50% saturated ammonium 
acetate. The precipitates were collected by centrifugation 
and redissolved in 20 mM ammonium acetate buffer (pH 
7.2), containing 20% glycerol, to a protein concentration f 
20 mg/ml. This cytochrome bc~ complex was then mixed 
with 0.5 M MOPS buffer (pH 7.2), and 2% detergent 
(DMG, decanoyl-N-methylglucamide or SPC, short side 
chained phosphotidyl choline) solution to a final concen- 
tration of 50 mM MOPS and 0.1% detergent. A 0.57 to 
one volume of 12% PEG-4000 in 50 mM MOPS buffer 
containing 0.5 M KC1, 20% glycerol, and 0.1% detergent 
was slowly added to the cytochrome bcj complex solution 
with constant stirring. After 2 h incubation at 0°C, the 
mixture was centrifuged for 10 rain at 40000 Xg to 
remove precipitates formed, if any. The clear solution was 
used for crystallization. For a quick test, 4-1xl aliquots 
were used for hanging drop set-up, equilibrated with 200 
txl of equilibrating solution, containing 18% PEG, 0.5 M 
KCI 20 mM Tris-Cl buffer (pH 7.0). Under these condi- 
tions, crystals formed overnight. To grow crystals for 
X-ray diffraction. 30- to 50-1M aliquots of centrifuged 
mixture were placed in small test tubes (6 X 50 mm) and 
incubated with equilibrating solution at 0 to 4°C. Crystals 
were mature in 3-4 weeks. Crystals are rectangular in 
shape, ranging in size from 0.5 to 1 mm. They can be 
frozen at high concentration glycerol. Under cryogenic 
conditions (100 ° K) these crystals diffract X-rays up to 2.9 
resolution using a synchrotron source. These crystals 
were used for data collection. These crystals have the 
symmetry of body-centered tetragonal s ~ace group of I4122 
and cell dimensions of a = b = 153.5 A and ¢ = 597.7 A. 
There are eight b¢ 1 dimers in a unit cell. Fig. 1 shows 
crystals of cytochrome b¢ 1 complex grown in 20% glyc- 
erol. 
Following our first report of crystallization of cy- 
tochrome bc~ complex in 1991 [37], several other investi- 
gators have also reported crystallization of this complex in 
various forms and with varying difractability. Table 1 
summarizes the crystals obtained by different investigators. 
4. Properties of cytochrome bc 1 complex crystals 
Crystalline cytochrome bc 1 complex is in the oxidized 
state and is composed of ten protein subunits. The complex 
contains 2.5 nmol ubiquinone, 8.4 nmol cytochrome b, 4.2 
nmol cytochrome q,  and 140 nmol phospholipid per mg 
protein. About 36% of the phospholipid associated with 
crystalline cytochrome bc 1 complex is diphosphatidyl- 
glycerol. These crystals are very stable in cold and show 
full enzymatic activity when redissolved in aqueous olu- 
tion. Absorption spectra of the redissolved crystals how a 
Soret to UV ratio of 0.88 and 1.01 in the oxidized and the 
reduced forms, respectively. 
Cytochrome bc~ complex crystals are not very stable 
under X-ray beam at 4°C, but are very stable in the frozen 
state. At 100°K the crystal suffers no noticeable damage 
even after 24 h of bombardment with under X-ray beam 
from a synchrotron source. A single crystal is sufficient for 
a complete set of data collection. 
5. Co-crystallization of cytochrome bc~ complex-in- 
hibitor complexes 
The cytochrome bc~ complex was precipitated by am- 
monium acetate as described in crystallization of native 
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complex and redissolved in 50 mM MOPS buffer (pH 7.2), 
containing 20 mM ammonium acetate, 20% glycerol, and 
0.14% SPC (or 0.11% DMG). This solution was incubated 
with a slightly molar excess of electron transport inhibitors 
[24], individually or in combination at 4°C for 30 min 
before being subjected to crystallization using the precipi- 
tating solution (0.57 volume) described for the native 
complex. The molar ratios used were 1.3, 2.1, 1.3, and 1.3 
for antimycin, UHDBT, myxothaizole, and stigmatellin, 
respectively. The inhibitor solutions were made in 95% 
ethanol to a concentration of approx. 10 mM. Crystals of 
inhibitor complexes appeared in 3-4 weeks. The shapes 
and sizes of crystals of inhibitor-complexes were very 
similar to those of the native cytochrome bcl complex and 
also diffracting X-rays to a resolution comparable tonative 
crystals. 
6. Co-crystallization of cytochrome bcl complex-cyto- 
chrome c complex 
The cytochrome bc I complex was precipitated by am- 
monium acetate as described in crystallization of native 
complex and redissolved in 50 mM MOPS buffer (pH 7.2), 
containing 20 mM ammonium acetate, 20% glycerol, 
0.14% SPC and incubated with a slightly molar excess (1.1 
to 1) of beef heart cytochrome c. After incubation for 1 h 
at 0-4°C the mixture was subjected to crystallization using 
0.46 volume of precipitating buffer solution or 0.51 vol- 
ume of precipitating buffer solution containing no KCI. 
The crystals of cytochrome bc I complex/cytochrome c 
complex formed within 4 weeks. The presence of cy- 
tochrome c in the crystals was confirmed by spectral 
analysis. The crystals were washed thoroughly and redis- 
solved in Tris-C1 buffer containing 0.1% deoxycholate. 
The molar ratio of cytochrome c:cytochrome bc I complex 
was found to be 0.75 and 1.0 in the crystals grown in the 
presence and absence of KC1, respectively. Preliminary 
results indicate that crystals of the cytochrome c/cyto- 
chrome bc I complex diffract X-rays to a resolution similar 
native crystals. 
The electron density map for the bc 1 complex clearly 
shows the close interaction between two crystallographic 
symmetry related monomers (Fig. 2). The dimer can be 
divided into three regions, the trans-membrane h lix re- 
gion, the matrix region, and the inter-membrane space 
region. The majority of the molecular mass is located in 
the matrix region of the molecule, extruding from the 
trans-membrane helix region by 75 A. The inter-membrane 
space region extrudes 41 A into the cytoplasmic surface 
from the trans-membrane h lix re~ion. The trans-mem- 
brane helix region is about 35 A thick with thirteen 
transmembrane h lices in each monomer. 
8. ~ izat ion  of redox centers 
Four high peaks in maps calculated using anomalous 
scattering data were interpreted as the redox-centers of the 
bc~ complex. Two of these sites are 20 A apart in the 
transmembrane region and are assigned to the heine irons 
of cytochromes b562 and b565, with the b562 close to the 
middle of the membrane and the b565 near the surface of 
the membrane. Another site near the cytoplasmic surface 
of the membrane and 27 A away from the nearest b-heme 
is the iron-sulfur center. The fourth site is the cytochrome 
c~ heme, which is 31 A apart from the iron-sulfur center. 
The distance between the b565s of the two monomers is 
less than 21 A, making the interaction between these two 
cytochromes very interesting. The relative locations of 
redox centers are indicated in Fig. 3. Some of the locations 
of redox centers and the distances between them deter- 
mined here are very close to those obtained from the 
biochemical and biophysical studies [47-49]. 
7. Structural analysis 
Crystals grown in the ~presence of glycerol diffract 
X-rays to better than 3 A resolution under cryogenic 
conditions. The diffraction quality of heavy metal deriva- 
tized crystals is comparable to that of native crystals. 
Initial MIR phases were determined with four heavy metal 
derivatives. Electron density maps obtained with the MIR 
phases were subsequently improved with cyclic density 
modification procedures. Better phases were then used to 
improve further the initial MIR phases. 
Fig. 3. The relative locations of redox centers of crystalline dimeric 
cytochrome bc I complex. 
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9. Localization of inhibitor binding domains 
Even without three-dimensional structural information, 
studies of interactions between inhibitors and electron 
transfer complexes have made significant contributions in 
the electron transfer pathway. For instance, antimycin inhi- 
bition of the cytochrome bc~ complex has been extensively 
studied. Antimycin blocks electron exit from cytochrome 
b562 and causes red spectral shift. Binding of antimycin to 
the cytochrome bcj complex also destabilizes the ubisemi- 
quinone radical at the Qi site. It is generally believed that 
antimycin binds near the b562. Inhibitor-resistant mutant 
analysis also suggests that antimycin binds on the matrix 
side of the inner membrane [36,50]. 
Differences between the electron density maps calcu- 
lated from X-rays diffraction data of antimycin-bound and 
native bc I complex reveal a strong area of density whose 
shape resembles that of antimycin. This density is located 
extremely close to the b562, causing local conformational 
changes both to the heme and to nearby residues. 
Another highly potent and specific inhibitor of electron 
transfer in the cytochrome bc 1 segment of the respiratory 
chain is UHDBT (5-undeceyl-6-hydroxy-4,7-dioxoben- 
zothiazoi). UHDBT blocks electron transfer between the 
Rieske iron-sulfur and cytochrome c I [51] and inhibits 
oxidant-induced cytochrome b reduction [52]. It is gener- 
ally believed that this inhibitor binds near the iron-sulfur 
cluster, causing modification of EPR signals from the 
iron-sulfur cluster. Preliminary analysis of the difference 
electron density maps between the UHDBT-cytochrome 
bc~ complex and the native complex also indicates that the 
dioxobenzothiazol part of UHDBT is likely to bind near 
the iron-sulfur cluster. More detailed analysis is needed 
before the precise binding site of this inhibitor can be 
established. 
Structural analyses of crystals of other inhibitor com- 
plexes and cytochrome c:cytochrome bc~ complex are 
currently in progress in our laboratories. 
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